Limula

Are you in Rome 🇮🇹 this week for the annual meeting of the European Society of Gene and Cell Therapy? Do you want to discover disruptive innovation in cell therapy manufacturing automation? 📣 Reach out! Luc Henry, Olivier Waridel and Luca Bellosta are available to discuss your needs and explore how our unique technology can support you. #ESGCT2024 #CGT #Manufacturing #Automation

📣 We crossed the 𝟱 𝟬 𝟬 𝟬 followers mark! A big thank you to every single one of you - We believe it is a testimony of how much our vision and mission resonate with the Cell and Gene Therapy community. Now spread the word and let's bring another 5000 people on board! #cellandgenetherapy #manufacturing #automation

👨🔬 "Limula is making life-saving cell therapies accessible to patients at scale through manufacturing automation" Oxford Seed Fund backed Limula in our last batch of investments - Limula is revolutionizing Cell & Gene Therapy (#CGT) manufacturing with an all-in-one device that automates the complex process end-to-end, paving the way for scalable, personalized cancer treatments. 🔬 CGT therapies hold incredible promise for treating cancers and other serious diseases, but they're currently difficult to produce. Today’s manufacturing is complex, involving multiple manual steps in clean rooms, which limits capacity and increases costs. 👥 Led by CEO Dr. Luc Henry, a DPhil graduate in Chemical Biology from University of Oxford, the founding team brings together deep expertise in micro-engineering, immuno-oncology, and project management, with backgrounds from #Oxford, EPFL, and the University of Basel. 🔍 Top 3 reasons Oxford Seed Fund invested: Game-Changing Technology: Limula's device is the only true end-to-end solution in CGT manufacturing. Its strong patent and flexibility mean it tackles the entire value chain, built directly with customer insights. Outstanding Team: The multidisciplinary founding team and early hires bring both academic excellence and real-world commercial experience, instilling confidence in their ability to execute. Huge Market Opportunity & GTM: With a strategy to first address niche applications and then expand, Limula is well-positioned to become a key hardware standard in a CGT market projected to reach $60B by 2030. We believe in Limula's vision and their ability to drive innovation in CGT manufacturing, ultimately making personalized therapies more scalable, affordable, and accessible. Here's to enabling the future of medicine! 🧬

𝐋𝐚 𝐛𝐢𝐨𝐜𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐜𝐞 𝐩𝐨𝐮𝐫 𝐠𝐚𝐠𝐧𝐞𝐫 𝐝𝐮 𝐭𝐞𝐦𝐩𝐬 𝐟𝐚𝐜𝐞 à 𝐥𝐚 𝐦𝐚𝐥𝐚𝐝𝐢𝐞 La start-up vaudoise Limula illustre la tendance de la #bioconvergence. Elle a conçu un appareil faisant appel aussi bien au #génie mécanique qu’à l’#immunologie pour lutter contre le #cancer. Un article de Ghislaine Bloch, Gilles Weder (CSEM) , Luc Henry, Abionic #biotechnologie #informatique #digitalisation #ingénierie #traitement #médecine #science #biologie #recherche

First cancer, then autoimmune diseases, now asthma, heart disease—and even ageing. Great coverage of the expanding scope of CAR-T therapy in The Economist last week. Sub-title says it all: "Making treatment quick and affordable will be the challenge" A must read if you want to understand the context (and potential impact) of what we do at Limula — Our vision: Automated. Scalable. Accessible. https://lnkd.in/eKbr8HvZ #CGT #CellTherapy #Manufacturing #Automation

Proud to be amongst the 15 promising 🇨🇭 Biotech Startups that made it in the TOP100 list this year - Thank you Venturelab for highlighting our work!

This week our CEO Luc Henry will present Limula at the Tech Tour Growth Health 2024 event on 10-11 September in Lausanne 🇨🇭 We are looking for partners and investors who want to be part of the Cell & Gene Therapy revolution! Our innovative manufacturing platform is progressing fast in its development and is now being tested at multiple sites across Europe. Come see the pitch or reach out to know more: partnerships@limula.ch

Are you interested in beta-testing a highly innovative Cell & Gene Therapy manufacturing automation solution? Are you in Göteborg 🇸🇪 next week to attend the ISCT Europe meeting? Limula will present T cell expansion data collected on a functional bioreactor sub-system of our ground-breaking technology. Our CEO Luc Henry and biologist Carolina Jiménez Navarro will be available to answer your questions during the poster session II on Thursday 5 September at 17:45-19:15. You can also book a 1:1 meeting or contact us by email to start a conversation: partnerships@limula.ch #ISCTEurope2024 #celltherapy #CART #manufacturing #automation

What is a 'docpreneur'? Here is one we are grateful to count as member of Limula Strategic Advisory Board: Denis Migliorini, clinician at Université de Genève, professor of neuro-oncology, and co-founder of Cellula Therapeutics SA. https://lnkd.in/dHrW_eJk via Biopôle Lausanne

We are excited to share our latest testimonial film for the Lichtsteiner Foundation featuring Limula and its 3 co-founders Luc Henry, Thomas Eaton and Yann Pierson. Motivated by “having a hard problem that is worth solving”, Limula are leading the way in making a brand new type of cancer treatment accessible, by automating the manufacturing of CAR T and other cell therapies. Their team strives to “bring breathtaking personalized cell therapies to all of the eligible patients”.  As the company continues to grow, expand its team, and refine its technology, it remains committed to meeting the rising demand for tools supporting cutting-edge biotech innovation. #Limula #LichtsteinerFoundation #Biotechnology #CellTherapy #Manufacturing #Automation